Gotratix (A-18, muscle bioregulator)
Short-peptide muscle bioregulator from the Khavinson tissue-specific framework.
At a glance
What it is: Short-peptide muscle bioregulator from the Khavinson tissue-specific framework..
Primary research applications:
- Skeletal-muscle bioregulator research (Khavinson framework)
- Recovery and athletic-performance discussion
Editorial summary: Gotratix is a Khavinson-tradition short peptide proposed as a tissue-specific bioregulator for skeletal muscle. The evidence base sits within the broader Khavinson lineage — interesting framework, real research-group output, and limited independent Western validation.
- Class / structure
- Short peptide (typically 3-4 amino acids) within the Khavinson bioregulator family
- Half-life
- Very short systemic half-life; framework-specific tissue interactions
- First described
- Khavinson group, post-2000
- Regulatory status
- Sold as a supplement / research-grade peptide; not FDA-approved
What is Gotratix?
Gotratix is a short peptide marketed as a skeletal-muscle bioregulator within the Khavinson bioregulator framework.
Discovery and development
Gotratix is part of the broader family of Khavinson-tradition peptide bioregulators. The Khavinson group's framework proposes that short peptides selectively support function in specific organ systems — Gotratix is positioned within this framework as the muscle-specific bioregulator.
The compound is sold as a supplement / research-grade peptide and is part of the bioregulator product portfolio that includes Pinealon, Cortagen, Vesugen, Bonothyrk, and others.
Mechanism of action
Within the Khavinson framework, Gotratix is proposed to reach the cell nucleus in skeletal-muscle tissue and modulate gene expression in a tissue-selective way. Independent confirmation of this mechanism outside the originating group is limited.[1]
Pharmacokinetics
Plasma half-life is very short, consistent with the broader Khavinson short-peptide family. The proposed mechanism of action is direct DNA / nuclear interaction in target tissue, a claim that remains controversial outside the originating research lineage.
What the research shows
The peer-reviewed literature on Gotratix is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Selectively supports skeletal-muscle function as a bioregulator | Khavinson framework hypothesis | Uncertain |
| Has independently replicated effects outside the Russian research lineage | Limited | Uncertain |
| Should be considered an established muscle-recovery therapy | Not at Western evidence-grading levels | Unsupported |
Reported user experiences
How the research describes administration
Typically administered as oral capsules in supplement form, consistent with the rest of the Khavinson peptide product line.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Gotratix is a representative member of the Khavinson tissue-specific bioregulator family — interesting conceptually, with a real but lineage-concentrated research base. For readers exploring this space, the appropriate framing is curiosity about the underlying "tissue bioregulator" concept paired with explicit recognition that the Western evidence-grading framework has not yet been satisfied for individual claims about this compound.
Frequently asked questions
How does Gotratix relate to the Khavinson bioregulator framework?
Gotratix is one of the muscle-targeted entries in the Khavinson framework. The framework proposes that each peptide selectively supports function in a specific tissue — Pinealon for cognition, Vesugen for vasculature, Bonothyrk for bone, Gotratix for muscle, etc.
References
- Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12422308/
- Khavinson VK, Linkova NS. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2020;10:34-45. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+peptide+bioregulator